Chemetics® small molecule drug discovery as Nature would have done it

Nuevolution A/S is a unique company poised to revolutionize lead discovery by utilising its proprietary Chemetics®  technology to synthesize and identify hundreds of diverse drug leads to pharmaceutically important therapeutically targets.

Chemetics® represents the ultimate “convergent” fragment based lead discovery technology. It is a unique, patent protected hybrid of proven wet chemistry and molecular biology that enables the rapid synthesis and selection of ligands from millions to billions of drug-like compounds in a single test tube.

By applying Chemetics® to recognised disease targets, Nuevolution has identified novel, drug-like, small molecules with the potential to address major unmet medical needs within important disease areas.

The company was founded in May 2001 and is headquartered in Copenhagen, Denmark, in the heart of the biotech cluster Medicon Valley, comprising the Greater Copenhagen area and Southern Sweden.

To date, Nuevolution has raised € 37 million in venture capital based on the ongoing development of its proprietary Chemetics® technology. Investors include Novo A/S, SLS Invest,, SEB Venture and SunStone Capital.